Tc Biopharm Plc Stock Performance
| TCBPW Stock | USD 0.01 0 20.83% |
On a scale of 0 to 100, TC BioPharm holds a performance score of 2. The firm owns a Beta (Systematic Risk) of -5.65, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning TC BioPharm are expected to decrease by larger amounts. On the other hand, during market turmoil, TC BioPharm is expected to outperform it. Please check TC BioPharm's information ratio and the relationship between the value at risk and price action indicator , to make a quick decision on whether TC BioPharm's current price history will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in TC BioPharm plc are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, TC BioPharm showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:50 | Last Split Date 2022-11-21 |
1 | Is it Time to Dump TC BioPharm Ltd Stock After it Has Fallen 20.00 percent in a Week - InvestorsObserver | 03/19/2024 |
2 | TC Biopharm shares jump on signing non-binding LOI for two allogeneic CAR-NK therapeutics - Seeking Alpha | 04/04/2024 |
3 | TC Biopharm Announces Corporate Restructuring, Reduction in Overhead - The Globe and Mail | 05/30/2024 |
| Begin Period Cash Flow | 4.8 M | |
| Free Cash Flow | -10.8 M |
TCBPW |
TC BioPharm Relative Risk vs. Return Landscape
If you would invest 4.00 in TC BioPharm plc on March 14, 2024 and sell it today you would lose (2.86) from holding TC BioPharm plc or give up 71.5% of portfolio value over 90 days. TC BioPharm plc is currently producing 0.9404% returns and takes up 26.676% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than TCBPW, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
TC BioPharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TC BioPharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as TC BioPharm plc, and traders can use it to determine the average amount a TC BioPharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0353
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TCBPW | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 26.68 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.94 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average TC BioPharm is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TC BioPharm by adding it to a well-diversified portfolio.
TC BioPharm Fundamentals Growth
TCBPW Stock prices reflect investors' perceptions of the future prospects and financial health of TC BioPharm, and TC BioPharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TCBPW Stock performance.
| Return On Equity | -5.57 | ||||
| Return On Asset | -1.09 | ||||
| EBITDA | (17.35 M) | ||||
| Net Income | (5.91 M) | ||||
| Cash And Equivalents | 1.55 M | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.8 M | ||||
| Current Ratio | 0.18 X | ||||
| Book Value Per Share | (0.65) X | ||||
| Cash Flow From Operations | (10.54 M) | ||||
| Earnings Per Share | (0.75) X | ||||
| Total Asset | 8.93 M | ||||
| Retained Earnings | (38.84 M) | ||||
| Working Capital | 950.33 K | ||||
About TC BioPharm Performance
To evaluate TC BioPharm plc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when TC BioPharm generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare TCBPW Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand TC BioPharm plc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents TCBPW's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.91) | (0.95) | |
| Return On Capital Employed | (4.34) | (4.56) | |
| Return On Assets | (0.84) | (0.89) | |
| Return On Equity | (2.80) | (2.66) |
Things to note about TC BioPharm plc performance evaluation
Checking the ongoing alerts about TC BioPharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TC BioPharm plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TC BioPharm plc is way too risky over 90 days horizon | |
| TC BioPharm plc has some characteristics of a very speculative penny stock | |
| TC BioPharm plc appears to be risky and price may revert if volatility continues | |
| TC BioPharm plc has a very high chance of going through financial distress in the upcoming years | |
| TC BioPharm plc has accumulated 1.8 M in total debt. TC BioPharm plc has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about TC BioPharm's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (5.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TC BioPharm plc has accumulated about 1.55 M in cash with (10.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| TC BioPharm plc has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: TC Biopharm Announces Corporate Restructuring, Reduction in Overhead - The Globe and Mail |
- Analyzing TC BioPharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TC BioPharm's stock is overvalued or undervalued compared to its peers.
- Examining TC BioPharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TC BioPharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of TC BioPharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TC BioPharm's stock. These opinions can provide insight into TC BioPharm's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for TCBPW Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.